Form 4: Acrivon Therapeutics Chief Accounting Officer Reports Tax Withholding Transaction
SEC Filing
Katharine Peterson, Chief Accounting Officer of Acrivon Therapeutics, reports the withholding of shares to cover tax obligations upon vesting of restricted stock units.
Summary
- On February 14, 2025, Katharine Peterson, the Chief Accounting Officer of Acrivon Therapeutics, Inc., reported a transaction on Form 4.
- The transaction involved the withholding of 116 shares of common stock at a price of $5.42 per share to satisfy tax withholding requirements upon the vesting of restricted stock units.
- Following the transaction, Peterson directly owns 4,419 shares of Acrivon Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to tax withholding, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC for corporate insiders, providing transparency into their transactions in the company's stock.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a standard tax withholding procedure.
Key Dates
| Date | Description |
|---|---|
| 02/14/2025 | Date of transaction (stock withholding for tax obligations). |
| 02/19/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.